Adult: In patients with ALK-positive tumours whose disease have progressed on crizotinib and ≥1 other ALK inhibitor, or alectinib or ceritinib as the first ALK tyrosine kinase inhibitor (TKI) therapy: 100 mg once daily, given continuously until disease progression or unacceptable toxicity. Dose reduction, dosing interruption, or discontinuation may be required according to individual safety or tolerability (refer to detailed product guideline). Dose reductions are made in 25-mg steps. Discontinue permanently if the patient is unable to tolerate 50 mg once daily.
Special Patient Group
Patients taking concomitant strong CYP3A4 inhibitors: Initially, 75 mg once daily. If dose reduction to 75 mg once daily has been made to manage adverse effects, reduce further to 50 mg once daily.
Severe: Not recommended.
Moderate to severe: Not recommended.
film-coated tab: May be taken with or without food. Preferably taken at the same time each day. Swallow whole, do not chew/crush/split.
Pregnancy and lactation. Concomitant use with strong CYP3A inducers.
Moderate to severe hepatic and severe renal impairment. Patients taking concomitant strong CYP3A4 inhibitors and moderate CYP3A inducers.
Significant: Anaemia, mild lymphopenia and thrombocytopenia, CNS effects (e.g. seizures, psychotic effects [e.g. hallucinations], changes in cognitive function, mood [including suicidal ideation, anxiety, depression], speech, mental status and sleep), AV block, PR interval prolongation, reduced LVEF, increased serum cholesterol, triglycerides, amylase and lipase. Eye disorders: Diplopia, photophobia, photopsia, blurred vision, visual impairment, reduced visual acuity, vitreous floaters. Gastrointestinal disorders: Diarrhoea, constipation, nausea. General disorders and administration site conditions: Fatigue, asthenia. Investigations: Increased weight. Metabolism and nutrition disorders: Oedema. Musculoskeletal and connective tissue disorders: Arthralgia, myalgia. Nervous system disorders: Peripheral neuropathy, headache. Skin and subcutaneous tissue disorders: Rash. Potentially Fatal: Interstitial lung disease or pneumonitis.
Patient Counseling Information
This drug may cause CNS effects (e.g. seizures, hallucinations), if affected, do not drive or operate machinery.
Establish ALK positivity using a validated ALK assay and evaluate pregnancy status prior to initiation of therapy. Monitor serum cholesterol, triglycerides, ECG, AST/ALT, bilirubin, amylase and lipase elevations; signs and symptoms of CNS effects and interstitial lung disease/pneumonitis.
Decreased plasma concentrations with moderate CYP3A inducers. Increased plasma concentrations with strong CYP3A inhibitors (e.g. itraconazole, boceprevir, ritonavir, cobicistat, troleandomycin). Reduced plasma concentrations of CYP3A substrates with narrow therapeutic indices (e.g. fentanyl, ciclosporin, ergotamine, hormonal contraceptives, pimozide, quinidine, sirolimus) and P-glycoprotein substrates (e.g. digoxin, dabigatran). Potentially Fatal: Increased AST/ALT with concomitant use of strong CYP3A inducers (e.g. rifampicin, phenytoin, carbamazepine, mitotane, enzalutamide) which may lead to severe hepatotoxicity.
Reduced plasma concentrations with St. John’s wort; avoid concomitant use. Increased plasma concentrations with grapefruit products.
Description: Lorlatinib is an inhibitor of multiple tyrosine kinases, including anaplastic lymphoma kinase (ALK) and c-rosoncogene-1 (ROS1), as well as TYK1, FER, FPS, TRKA, TRKB, TRKC, FAK, FAK2 and ACK. It inhibits phosphorylation of ALK and ALK-mediated signal transduction, thus reducing cellular proliferation and survival in tumours which express these fusion proteins. Pharmacokinetics: Absorption: Rapidly absorbed. Bioavailability: 81%. Time to peak plasma concentration: Approx 0.5-4 hours. Distribution: Crosses the blood-brain barrier. Plasma protein binding: 66%. Metabolism: Metabolised mainly via oxidation by the CYP3A4 and via glucuronidation by the UDP-glucuronosyltransferase1A4 (UGT1A4), with minor contributions from CYP2C8, CYP2C19, CYP3A5 and UGT1A3. Excretion: Via urine (48%, <1% as unchanged drug) and faeces (41%, approx 9% as unchanged drug). Elimination half-life: 24 hours.
Store between 20-25°C. This is a cytotoxic drug. Follow applicable procedures for receiving, handling, administration, and disposal.
L01ED05 - lorlatinib ; Belongs to the class of anaplastic lymphoma kinase (ALK) inhibitors. Used in the treatment of cancer.
Anon. Lorlatinib. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 09/02/2020.Anon. Lorlatinib. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 09/02/2020.Buckingham R (ed). Lorlatinib. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 09/02/2020.Joint Formulary Committee. Lorlatinib. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 09/02/2020.Lorbrena Tablet, Film Coated (Pfizer Laboratories Div Pfizer Inc). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 09/02/2020.Lorbrena Tablets (Pfizer Inc). U.S. FDA. https://www.fda.gov. Accessed 09/02/2020.Lorviqua 25 mg and 100 mg Film-Coated Tablets (Pfizer Europe MA EEIG). MHRA. https://products.mhra.gov.uk. Accessed 09/02/2020.